Clinical Trials Logo

Human Immunodeficiency Virus (HIV) clinical trials

View clinical trials related to Human Immunodeficiency Virus (HIV).

Filter by:

NCT ID: NCT03800394 Recruiting - Tuberculosis Clinical Trials

Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents

Start date: January 28, 2019
Phase:
Study type: Observational

Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa. In addition, TDF/FTC is recommended for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection in adolescents at substantial risk of acquisition of HIV infection, as well as for hepatitis B virus (HBV) treatment in those with HBV/HIV coinfection. The efficacy TDF and FTC are dependent on intracellular concentrations of the active phosphate anabolites, called TFV diphosphate (TFV-DP) and FTC triphosphate (FTC-TP). However, the intracellular pharmacokinetics of TFV-DP and FTC-TP to examine the adequacy of current dosages in African adolescents has not been previously studied. Thus, examining the pharmacokinetics (PK) of these widely used antiretrovirals in African adolescents is important as ART outcomes remain poor and the recommended dosages of these drugs for children and adolescent were extrapolated from drug approval clinical trials in adult in the United States and Europe.

NCT ID: NCT03783130 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults<TAB>

Start date: February 20, 2019
Phase: Phase 1
Study type: Interventional

Background: HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection. Researchers want to test a vaccine called Trimer 4571 for the first time. It was made at the National Institutes of Health and contains no HIV. It will be given mixed with a substance called alum to boost the body s immune response to the vaccine. Alum has been used in licensed vaccines for over 60 years and has been found to be safe. Objectives: To see if the vaccine Trimer 4571 is safe, well-tolerated, and to study immune responses to it. Eligibility: Healthy adults ages 18-50 years Design: Participants will be screened with a physical exam and blood tests. They must agree to not become pregnant and to avoid behavior that will put them at high-risk for HIV infection during the study. Participants will have about 15 study visits over about 9 months. The first 6 participants will get a low dose of the vaccine mixed with alum. Once that is deemed safe, 10 new participants will get a higher dose. All participants will be randomly assigned to get the vaccine by injection in a muscle or under the skin. All participants will get a total of 3 vaccine injections over 20 weeks. Each visit where participants receive the vaccine will last about 5 hours. Participants will be watched after each injection. Participants able to get pregnant will have a pregnancy test before each injection. Participants will get a thermometer and record their temperature and symptoms every day for 1 week after each injection. They will also check the injection site for redness, swelling, or bruising. At follow-up visits, participants will have blood drawn and be checked for health changes or problems. Follow up visits will last about 1-2 hours.

NCT ID: NCT03617705 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Alcohol Monitor Validation

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This study will validate a wrist-worn alcohol monitor (BACtrack Skyn) in both laboratory and real-life settings.

NCT ID: NCT03577470 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate

DIAMANTE
Start date: June 13, 2018
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot algorithm through collection of daily practice data in the Italian setting.

NCT ID: NCT03489421 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Mitochondria in HIV and Aging (MITO+)

(MITO+)
Start date: December 15, 2018
Phase:
Study type: Observational

Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy. This dysfunction in mitochondria may lead to symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI). Furthermore, the investigators hypothesize that the older antiretroviral therapy (ART) of tenofovir disoproxil fumarate (TDF) is associated with greater impairment in mitochondrial function than the newer agent, tenofovir alafenamide (TAF).

NCT ID: NCT03407105 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Start date: April 21, 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects

NCT ID: NCT03290755 Completed - Hepatitis c Clinical Trials

Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux

HEPCSEX
Start date: November 8, 2017
Phase:
Study type: Observational

The main objective of this study is to analyse sexual behavior of HIV + MSM in Bordeaux, who have sexually contracted hepatitis C between January 1st 2013, to January 31, 2017. These data will bring some improvement about prevention and maybe reduced the hepatitis C incidence.

NCT ID: NCT02974998 Active, not recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Expanding HIV Testing and Prevention to Reach Vulnerable Young Women

Start date: November 2016
Phase: N/A
Study type: Interventional

This two-arm cluster randomized trial is testing a gender-focused comprehensive HIV testing and counselling (HTC) program, the Young Women's Health CoOp (YWHC) with a standard HTC program and will target female adolescents (aged 16-19) who use substances and have dropped out of school. To evaluate the process, the study will examine the feasibility of using peer role models as recruiters and co-facilitators of the intervention and monitor fidelity to the intervention. Efficacy of the intervention on behavioral and biological outcomes, and on linkages to health services, through follow-up visits conducted 6- and 12-months post-enrollment will be also assessed.

NCT ID: NCT02965014 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

NC Young Women's CoOp

Start date: January 18, 2017
Phase: N/A
Study type: Interventional

This three-arm cross-over cluster-randomized trial will develop, test, and compare the efficacy of two delivery formats of the Women's CoOp (WC), which is designed to provide risk reduction and empowerment skills, as well as linkages to healthcare services for substance-using women. The current study will develop a revised version of the WC and evaluate the relative efficacy of a face-to-face (face-to-face WC), mobile Health application (mHealth WC) delivery format, and HIV counseling and testing (HCT) as a control to reduce risky sexual behaviors, reduce substance use, and increase sexual negotiation among young (18-25 years) substance-using African American women who are sexually active and have not recently been tested for HIV in three NC counties.

NCT ID: NCT02873741 Active, not recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

New Strategies to Assess Anal Cancer Risk In Women

ANCAR-WIHS
Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this research is to study different strategies to identify women at highest risk for anal cancer. Primarily, investigators want to study a risk assessment called the Anal Cancer Risk Index; it gives women an overall number score based on risk factors that they may have for anal cancer, such as age, number of sexual partners, or smoking. Investigators seek to understand whether women with higher Anal Cancer Risk Index scores are more likely to have abnormal results on anal pap smears, HPV tests, or anal biopsies. The study team will collect swabs of the cervix and the anus to study different laboratory tests that could identify women at highest risk of cervical and anal cancer. These laboratory tests include an anal pap smear, tests for markers of disease and tests that detect the HPV types most likely to cause cancer. The study team would like to see which of these laboratory tests do the best job at predicting precancerous lesions in the anus and are better indicators of risk for cancer. After collecting these swabs, women will have a procedure called high resolution anoscopy where investigators look closely at the anus and biopsy any suspicious areas. Finally, the study team will look for HPV proteins and changes that HPV can make in cells to see if these tests predict anal lesions.